Loading clinical trials...
Loading clinical trials...
MGCD516 is a receptor tyrosine kinase (RTK) inhibitor shown in preclinical models to inhibit a closely related spectrum of RTKs including MET, AXL, MER, and members of the VEGFR, PDGFR, DDR2, TRK and ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Mirati Therapeutics Inc.
NCT06813079 · Pancreatic Ductal Carcinoma, Advanced Cancer, and more
NCT05076760 · Solid Tumor, Advanced Cancer, and more
NCT06616298 · Advanced Cancer
NCT07260708 · Advanced Cancers
NCT05735080 · Breast Cancer, Breast Cancer Metastatic, and more
University of Alabama
Birmingham, Alabama
University of California, San Diego
San Diego, California
University of California, San Francisco
San Francisco, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions